It was reported here in November 2017 that two “anti-Ang2” drugs are being studied as potential combination therapies with established anti-VEGF treatments. RG7716 is being tested in combination with Lucentis (Genentech), and nesvacumab (REGN910) is being tested in combination with Eylea (Regeneron).
Genentech has now reported that its Phase 2 BOULEVARD trials with RG7716 have demonstrated clinically meaningful and statistically significant visual acuity improvements in people with diabetic macular edema.
In addition to BOULEVARD, RG7716 is also being evaluated in the Phase II AVENUE and STAIRWAY studies in wet AMD. All three studies have finished enrollment and are currently in follow-up. Genentech will discuss a Phase III program with the FDA following data assessment.
To keep up on progress of research in treatment of wet AMD, see Antiangiogenic Drugs Are Stopping Neovascularization in Wet Macular Degeneration on this site.